BioAge Labs Inc., a clinical-stage biotechnology firm growing therapies for weight problems and metabolic illness, is searching for to boost as a lot as $157.5 million in its preliminary public providing and a personal placement.
The corporate is providing 7.5 million shares for $17 to $19 apiece, based on a submitting Wednesday with the US Securities and Change Fee. Individually, Sofinnova Enterprise Companions XI LP, an present shareholder, is anticipated to buy about $15 million value of shares on the IPO value in a personal placement.
On the prime of the worth vary, BioAge would have a market worth of about $587 million, based mostly on the excellent shares listed within the submitting.
BioAge, based mostly in Richmond, California, had a valuation of $394 million after elevating $194 million in a Collection D spherical in February, based on information supplier PitchBook.
Its prime shareholders are co-founder and Chief Government Officer Kristen Fortney, who controls 9.8% of the corporate, and entities affiliated with Andreessen Horowitz and Khosla Ventures, with 9.4% and eight% useful possession respectively, the submitting exhibits.
The providing is being led by Goldman Sachs Group Inc., Morgan Stanley, Jefferies Monetary Group Inc. and Citigroup Inc. The corporate plans for its shares to commerce on the Nasdaq World Market below the image BIOA.
